Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer

BACKGROUND: The oestrogen receptor (ER) co-activator amplified in breast cancer 1 (AIB1) has been suggested as a treatment predictive and prognostic marker in breast cancer. Studies have however not been unanimous. PATIENTS AND METHODS: AIB1 protein expression was analysed by immunohistochemistry on...

Descripción completa

Detalles Bibliográficos
Autores principales: Weiner, M., Skoog, L., Fornander, T., Nordenskjöld, B., Sgroi, D. C., Stål, O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2013
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3718507/
https://www.ncbi.nlm.nih.gov/pubmed/23670096
http://dx.doi.org/10.1093/annonc/mdt159

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3718507/
https://www.ncbi.nlm.nih.gov/pubmed/23670096
http://dx.doi.org/10.1093/annonc/mdt159

Ejemplares similares